← Russell 3000 cross-section

SENS Senseonics Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Industrials

Scale

Market cap
$505m
Revenue TTM
$48m
Net income TTM
$-109m
Free cash flow
$-97m
Composite score
39.4
Sector rank
#2394

Valuation

P / E
EV / EBITDA
EV / sales
8.6
FCF yield
-19.18%
Earnings yield vs 10-yr
-26.40pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-225.3%
EBITDA margin
-219.4%
ROE
-121.1%
ROIC
-3,130.0%
Revenue growth
90.6%

Insider activity, last 90 days

Net open-market
$0.13m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Pursuant to the Commercialization Agreement, in the United States, Ascensia began providing sales support for the Eversense 90 product on October 1, 2020 and Ascensia ramped up sales activities and assumed commercial responsibilities for Eversense 90 during the second quarter of 2021. ​ In February 2022, we received approval from the FDA for Eversense E3. For the three months ended June 30, 2026 and 2025, sales to Ascensia accounted for 12.5% and 52.0% of total revenue, respectively. For the six months ended June 30, 2026 and 2025, sales to Ascensia accounted for 15.5% and 61.0% of total revenue, respectively. …Senseonics Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →